Phase 2 N=18 Dual MRI for Cardiopulmonary COVID-19 Long Haulers
Covid19
Primary: Red Blood Cell to Membrane (RBC:M) Ratio — 0.39; 0.51 ratio (RBC:M)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=53 Nebulised Rt-PA for ARDS Due to COVID-19
COVID
Primary: Efficacy - PaO2/FiO2 Ratio — 227; 209; 155; 248 mmHg (rounded)
N/A N=14 Effect of Respiratory Exerciser on Pulmonary Functions of COVID-19 Patients
Covid19 · Respiratory Function Loss · Coronavirus Infection
Primary: Change in Peak Expiratory Flow (Absolute Value) — 175; 160 ml/min — p=0.374
N/A N=65 Ventilator-induced Lung Injury Vortex in Patients With SARS-CoV-2
ARDS · Mechanical Ventilation Complication · Ventilator-Induced Lung Injury
Primary: Number of Participants Who Survived and Died — 1; 31; 14; 19 Participants
Phase 2 N=36 Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection
Severe Acute Respiratory Syndrome · Respiratory Failure · Acute Respiratory Distress Syndrome
Primary: PaO2/FiO2 Change (Increase) From Pre-to-post Intervention — 16.9; 29.8 percent change
Phase 2 N=5 Treat COVID-19 Patients With Regadenoson
COVID-19 · Lung Inflammation
Primary: Proportion of Patients Alive and Free of Respiratory Failure Through the 30-day Trial. — 100 Percentage of of patients alive and free
N/A N=224 Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS
Prone Positioning · High Flow Nasal Cannula · Acute Respiratory Distress Syndrome
Primary: Treatment Failure (Intubation or Death) — 45; 45 Participants
N/A N=417 The Use of Focused Lung Ultrasound in Patients Suspected of COVID-19
COVID-19
Primary: Mechanical Ventilation — 21 Participants
Phase 2 N=941 CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients
COVID-19 · Coronavirus · Coronavirus Infection
Primary: Score on the WHO 11-point Ordinal Scale for Clinical Improvement at 14 Days — 2; 2 score on a scale
Phase 2 N=34 Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients
COVID-19 · Sars-CoV2
Primary: Mechanical Ventilation or Death Endpoint — 2; 0 Participants
N/A N=384 Lung Ultrasound Implementation in the Management of Patients Hospitalized With COVID-19
Covid19
Primary: Hospitalists Who Adopt Lung Ultrasound — 4 Participants
Phase 2 N=29 Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia
Corona Virus Infection · SARS-CoV 2 · SARS Pneumonia
Primary: Number of Participants Transferred to Intensive Care Unit (ICU) — 4 Participants
Phase 2 N=99 Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19
COVID · Corona Virus Infection · Covid-19
Primary: Percent Change in D-dimer — -5.6; -2.4 percent daily change — p=0.24
Phase 2 N=101 The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection
COVID-19
Primary: Number of Participants With Worsening of COVID-19 Within 28 Days — 1; 1 Participants
N/A N=1,705 ED Lung Protective Ventilation to Reduce Complications
Mechanical Ventilation · Ventilator-associated Conditions · ARDS
Primary: Number of Patients That Experience Pulmonary Complications After Admission From the Emergency Department — 171; 38 participants
Phase 1 N=12 Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)
COVID · Sars-CoV2 · COVID-19
Primary: Number of Major Hemorrhagic Complications Within 14 Days of Initiation of Treatment — 0 Participants
N/A N=2 Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19
COVID-19
Primary: Oxygen Saturation by Pulse Oximetry — 92; 93.5; 94; 94 percentage of oxygen saturation
N/A N=91 Pandemic Triage Score in Patients With Known or Suspected Severe Acute Respiratory Syndrome (SARS) CoronaVirus (CoV) 2 Infection
SARS-CoV-2 Acute Respiratory Disease · Covid19
Primary: Number of Participants With Normal and Above Triage (STC-19) Score — 52; 12; 4; 5 Participants
N/A N=119 Myocardial Injury and Quality of Life After COVID-19
COVID-19 · Myocardial Injury · Myocarditis Post Infection
Primary: Percentage of Patients (%) Recovered From COVID-19 With a Decrease in the Global Contractility of the Left and Right Ventricles. — 19; 39; 48 Participants
Phase 2 N=25 Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19
Covid19 · Pneumonia, Viral
Primary: Count of White Blood Cells (WBC) After 99mTc-pertechnetate Aerosol Inhalation for Adverse Events Monitoring as Evaluation Safety of This Procedure in Patients With…
Phase 3 N=4 Contrast Enhanced Ultrasound in COVID-19
Covid19 · Multisystem Inflammatory Syndrome in Children (MIS-C)
Primary: Estimate the Proportion of Patients With Normal Perfusion Versus Area(s) of Hypoperfusion in Heart, Kidneys and/or Brain — 2; 1 Participants
Phase 2 N=46 Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury
CoronaVirus Induced Disease-2019 (COVID-19)
Primary: Percentage of Participants Alive and Without Respiratory Failure Through Day 28 — 86.4; 79.2 percentage of participants — p==0.599
Phase 1 N=80 COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.
COVID-19
Primary: Participants With Serious Adverse Events. — 12; 15 Participants
Phase 3 N=30 Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)
SARS-CoV 2 · ARDS
Primary: Change in Arterial Blood Oxygen Content to Fraction of Inspired Oxygen Ratio (PaO2/FiO2) — 10.7; 21.4; 61.1; 11.8 mmHg
Phase 2 N=72 A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
COVID · Covid-19 · Coronavirus
Primary: Number of Subjects Who Experienced Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs — 4; 23; 22; 1 Participants
Phase 2 N=200 Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19
SARS (Severe Acute Respiratory Syndrome) · Coronavirus
Primary: Change of Arterial Oxygenation at 48 Hours From Enrollment — 200; 183 ratio
Phase 2 N=63 Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants
COVID-19 Pulmonary Complications · COVID-19
Primary: Number of Participants With Respiratory Failure-free Survival — 27; 28 Participants — p=0.4099
Phase 4 N=103 The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19
Pulmonary Fibrosis · Interstitial Lung Disease · Respiratory Disease
Primary: Change in Forced Vital Capacity (FVC) — 147.55; 167.72 mL
N/A N=2,097 COVID-19 Watch + COVID-19 Pulse
Covid19
Primary: Difference in Days Alive and Out of Hospital — 29.5; 29.4 days
N/A N=25 Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients
Idiopathic Pulmonary Fibrosis
Primary: 6 Minute Walk Distance — -6.2; -15.3 meters